These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

845 related articles for article (PubMed ID: 15950718)

  • 1. Nasopharyngeal carcinoma.
    Wei WI; Sham JS
    Lancet; 2005 Jun 11-17; 365(9476):2041-54. PubMed ID: 15950718
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term treatment outcome of recurrent nasopharyngeal carcinoma treated with salvage intensity modulated radiotherapy.
    Hua YJ; Han F; Lu LX; Mai HQ; Guo X; Hong MH; Lu TX; Zhao C
    Eur J Cancer; 2012 Dec; 48(18):3422-8. PubMed ID: 22835782
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Undifferentiated nasopharyngeal cancer (UCNT): current diagnostic and therapeutic aspects.
    Altun M; Fandi A; Dupuis O; Cvitkovic E; Krajina Z; Eschwege F
    Int J Radiat Oncol Biol Phys; 1995 Jun; 32(3):859-77. PubMed ID: 7790274
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment outcome for synchronous locoregional failures of nasopharyngeal carcinoma.
    Chua DT; Wei WI; Sham JS; Cheng AC; Au G
    Head Neck; 2003 Jul; 25(7):585-94. PubMed ID: 12808662
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nasopharyngeal carcinoma: diagnosis, staging, and management.
    Neel HB
    Oncology (Williston Park); 1992 Feb; 6(2):87-95; discussion 99-102. PubMed ID: 1532503
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of plasma Epstein-Barr virus (EBV) DNA levels and serum EBV immunoglobulin A/virus capsid antigen antibody titers in patients with nasopharyngeal carcinoma.
    Shao JY; Li YH; Gao HY; Wu QL; Cui NJ; Zhang L; Cheng G; Hu LF; Ernberg I; Zeng YX
    Cancer; 2004 Mar; 100(6):1162-70. PubMed ID: 15022282
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Review of nasopharyngeal carcinoma.
    Jeyakumar A; Brickman TM; Jeyakumar A; Doerr T
    Ear Nose Throat J; 2006 Mar; 85(3):168-70, 172-3, 184. PubMed ID: 16615599
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Present status of management of nasopharyngeal carcinoma.
    Wei WI; Sham JS
    Expert Rev Anticancer Ther; 2001 Jun; 1(1):134-41. PubMed ID: 12113121
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Systemic treatment strategies and therapeutic monitoring for advanced nasopharyngeal carcinoma.
    Ma BB; Chan AT
    Expert Rev Anticancer Ther; 2006 Mar; 6(3):383-94. PubMed ID: 16503855
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Histological types of nasopharyngeal carcinoma in an intermediate risk area.
    Cammoun M; Ellouz R; Behi J; Attia RB
    IARC Sci Publ (1971); 1978; (20):13-26. PubMed ID: 215511
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Advances in nasopharyngeal carcinoma.
    Guigay J
    Curr Opin Oncol; 2008 May; 20(3):264-9. PubMed ID: 18391624
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Application of circulating plasma/serum EBV DNA in the clinical management of nasopharyngeal carcinoma.
    Yip TT; Ngan RK; Fong AH; Law SC
    Oral Oncol; 2014 Jun; 50(6):527-38. PubMed ID: 24440146
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nasopharyngeal carcinoma.
    Chan AT; Teo PM; Johnson PJ
    Ann Oncol; 2002 Jul; 13(7):1007-15. PubMed ID: 12176778
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Significance of cell-free Epstein-Barr virus DNA in monitoring prognosis of nasopharyngeal carcinoma].
    Cao SM; Min HQ; Gao JS; Hong MH; Xiao XB; Zhang CQ; Liu XD; Zhang AL; Guo X
    Ai Zheng; 2003 Mar; 22(3):302-6. PubMed ID: 12654192
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Epstein-Barr virus-related serology in nasopharyngeal carcinoma and controls.
    Henle W; Henle G; Ho JH
    IARC Sci Publ (1971); 1978; (20):427-37. PubMed ID: 215525
    [No Abstract]   [Full Text] [Related]  

  • 16. Undifferentiated carcinoma of nasopharyngeal type (UCNT): a Swiss single-institutional experience during 1990-2005.
    Sidler D; Thum P; Winterhalder R; Huber G; Haerle SK
    Swiss Med Wkly; 2010 May; 140(19-20):273-9. PubMed ID: 19950040
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic impact of EBV-related LMP-1, histologic type, and environmental factors in nasopharyngeal carcinoma in a German population.
    Dietz A; Logothetis CA; Helbig M; Flechtenmacher C; Rudat V; Dollner R; Wallner F; Bosch FX
    Onkologie; 2004 Aug; 27(4):345-50. PubMed ID: 15347888
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Plasma Epstein-Barr viral deoxyribonucleic acid quantitation complements tumor-node-metastasis staging prognostication in nasopharyngeal carcinoma.
    Leung SF; Zee B; Ma BB; Hui EP; Mo F; Lai M; Chan KC; Chan LY; Kwan WH; Lo YM; Chan AT
    J Clin Oncol; 2006 Dec; 24(34):5414-8. PubMed ID: 17135642
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of Epstein-Barr virus DNA measurement in plasma in the clinical management of nasopharyngeal carcinoma in a low risk area.
    Kalpoe JS; Dekker PB; van Krieken JH; Baatenburg de Jong RJ; Kroes AC
    J Clin Pathol; 2006 May; 59(5):537-41. PubMed ID: 16489178
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Correlation of DNA ploidy in fresh tumor tissues to prognosis of nasopharyngeal carcinoma].
    Han F; Wang HY; Xia YF; Liu MZ; Zhao C; Lu TX
    Ai Zheng; 2007 Sep; 26(9):1015-9. PubMed ID: 17927864
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 43.